ROR-γ: a new way to suppress androgen receptor expression?

Most of our readers will be familiar with the idea that progression of prostate cancer over time is associated with the expression of  androgen receptors (ARs) in prostate cancer tissue. … READ MORE …

The accurate assessment of risk profiles among high-risk prostate cancer patients

A key question in management of prostate cancer is the risk that a particular patient has disease — at the time of diagnosis — that will progress over time to become metastatic. The ability to answer this question with accuracy is fundamental to the need for aggressive, early treatment. … READ MORE …

Pathway Genomics’ Cancer Intercept test has a problem

Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct. … READ MORE …

The androgen receptor pathway … this morning in San Francisco

So today’s early morning session of the GU Oncology meeting was highly focused on the evolution of newer therapies affecting the androgen receptor pathways in the treatment of advanced and progressive forms of prostate cancer. … READ MORE …